文献速递糖尿病

可溶性尿激酶纤溶酶原激活物受体介导糖尿病对冠心病不良结局的影响

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究基于Emory心血管生物样本库4324例患者,随访中位6.9年,发现2型糖尿病与心血管死亡等不良结局风险升高相关,而校正suPAR水平后该关联大幅减弱,hs-CRP无此效应;suPAR介导了2型糖尿病对不良结局超过50%的影响。

要点

  • suPAR水平在2型糖尿病患者中更高,且介导了2型糖尿病对冠心病不良结局的大部分影响。
  • 校正suPAR后,2型糖尿病与心血管死亡的校正风险比从1.38降至1.18且不再显著。
  • hs-CRP未介导2型糖尿病对不良结局的影响,提示suPAR反映的炎症/免疫失调通路更具特异性。

核心结论

  • 2型糖尿病对冠心病患者不良结局的影响显著通过suPAR所反映的慢性炎症和免疫失调所介导。
  • 降低suPAR水平的新型疗法能否影响2型糖尿病患者的冠心病风险尚待进一步研究。

研究设计与样本

  • 研究纳入Emory心血管生物样本库中有或无冠心病的患者,测量suPAR和hs-CRP水平并随访。
  • 共4324例参与者,平均年龄64岁(SD 11.9),女性占36%,2型糖尿病占31.8%,中位随访6.9年。
  • 采用Fine和Gray或Cox比例风险模型校正人口学、临床和治疗变量,并进行基于回归的因果中介分析。

主要发现

  • 2型糖尿病患者的suPAR中位水平为3260 pg/mL(IQR 2503-4463),高于无2型糖尿病者的2792 pg/mL(IQR 2217-3600)。
  • 2型糖尿病与心血管死亡校正后风险升高相关(HR 1.38;95%CI 1.16,1.63;P<0.001)。
  • 校正suPAR后,2型糖尿病与心血管死亡的关联大幅减弱(HR 1.18;95%CI 0.99,1.40;P=0.1)。
  • 校正hs-CRP未产生类似减弱效应。
  • suPAR而非hs-CRP介导了2型糖尿病对不良结局超过50%的影响,其他结局也观察到类似结果。

临床怎么用

  • 在冠心病合并2型糖尿病患者中,suPAR水平可用于评估炎症/免疫失调介导的不良结局风险。
  • suPAR可能作为干预靶点,但降低suPAR能否改善冠心病风险尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes (T2D) is a significant risk factor for adverse outcomes in coronary heart disease (CHD). We investigated whether inflammation and immune dysregulation, measured using soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein (hs-CRP) levels, mediate this risk. RESEARCH DESIGN AND METHODS: Patients with and without CHD enrolled in the Emory Cardiovascular Biobank had suPAR (ViroGates, Denmark) and hs-CRP levels measured and were followed for 1) cardiovascular death, 2) a composite of incident myocardial infarction and cardiovascular death, and 3) all-cause death. Fine and Gray or Cox proportional hazards models adjusted for demographic, clinical, and treatment variables were used. Regression-based causal mediation analyses were performed. RESULTS: A total of 4,324 participants (mean [SD] age 64 [11.9] years, 36% women, 31.8% with T2D) were followed for a median of 6.9 years. SuPAR levels were higher in those with T2D (median [interquartile range] 3,260 [2,503-4,463] vs. 2,792 [2,217-3,600] pg/mL). T2D was associated with a higher adjusted risk (hazard ratio [HR] 1.38; 95% CI 1.16, 1.63; P < 0.001) of cardiovascular death that was greatly attenuated (HR 1.18; 95% CI 0.99, 1.40; P = 0.1) after adjustment for suPAR, but not hs-CRP, levels. Similar findings were observed for the other outcomes. SuPAR, but not hs-CRP, levels mediated >50% of the effect of T2D on adverse outcomes. CONCLUSIONS: The impact of T2D on adverse outcomes is significantly mediated through chronic inflammation and immune dysregulation, estimated using suPAR levels. Whether novel therapies for reducing suPAR levels will impact CHD risk in T2D warrants further investigation.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Sakr SM, Desai S, Medina-Inojosa J, et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease. Diabetes Care. 2026. PMID: 41533335. doi:10.2337/dc25-0940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。